Study of Postprandial Incretin Response in Women With Gestational Diabetes

Gestational Diabetes Mellitus Clinical Trial

Official title:

Reduced Postprandial GLP-1 Response in Gestational Diabetes Mellitus: a Fully Reversible Phenomenon

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01274052
• Other study ID #: KA-060015
• Status: Completed
• Phase: N/A
• First received: January 10, 2011
• Last updated: January 10, 2011
• Start date: March 2007
• Est. completion date: July 2008

Study information

• Verified date: January 2011
• Source: University Hospital, Gentofte, Copenhagen
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide and glucagon.

The researchers aimed to investigate whether women with gestational diabetes mellitus exhibit decreased postprandial GLP-1 responses, and if so, whether this deficiency ceases following delivery when normal glucose tolerance is reestablished.

Description:

The researchers investigated nineteen pregnant women in third trimester and again postpartum. At the experimental days we performed a mealtest and drew blood for analyses of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), insulin, C-peptide and glucagon.

The researchers aimed to investigate whether women with gestational diabetes mellitus exhibit decreased postprandial GLP-1 responses, and if so, whether this deficiency ceases following delivery when normal glucose tolerance is reestablished.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: July 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Normal haemoblobin

• Willingness to participate

Exclusion Criteria:

• First degree relative with diabetes

• Diabetes before pregnancy

• Positive islet cell- and GAD-65 autoantibodies

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes, Gestational
• Gestational Diabetes Mellitus

Intervention

Other:
• Meal test
Liquid meal test

Locations

Country	Name	City	State
Denmark	Department of Internal Medicine, Glostrup Hospital	Glostrup

Sponsors (4)

Lead Sponsor	Collaborator
University Hospital, Gentofte, Copenhagen	Aase and Ejnar Danielsens Foundation, The Danish Diabetes Association, The Novo Nordic Foundation

Country where clinical trial is conducted

Denmark,